USA-based CMO insulin manufacturing partner and biomanufacturer built to capture global insulin market share.
MayMag Biologics: Domestic Biomanufacturing Supply Chain & Federal Biologic CDMO Partner MayMag Biologics is a Dallas, Texas-based, USA-based cGMP contract development and manufacturing organization (CDMO) and FDA-registered 506(e) outsourcing facility under the Drug Quality and Security Act (DQSA). Operating dual cGMP-certified facilities in Dallas and Garland, Texas, MayMag provides pharmaceutical sponsors, research institutions, compounding pharmacies, and specialty distributors nationwide with a fully domestic U.S. supply chain—eliminating dependence on overseas API manufacturers.
Federal & Defense Contracting Credentials
Registrations & Compliance: Leading federal biologic CDMO partner, SAM.gov subcontractor, GSA/SAM registered biologic manufacturer, and FAR-compliant contract manufacturing pharma provider.
Codes & Standards: Certified for NAICS 325414 Biological Products, NAICS 325412 Pharmaceutical Preparations, 6505 Biologicals and Formal Compounds, and AI14 Defense R&D; medical pharmaceuticals, offering Berry Amendment-compliant pharmaceuticals and TAA-compliant drug manufacturing.
Sterile Biologics, API Synthesis & Fill-Finish Services
Peptides & Recombinant Proteins: Large-scale recombinant protein production, recombinant insulin API supplier services, and solid-phase peptide synthesis (SPPS) for GLP-1 agonists (tirzepatide and semaglutide analogs) and GLP-1/GIP dual agonists.
Biosimilar Insulins & Sterile Injectables: Large-scale biologics manufacturing and biosimilar drug manufacturing/compounding targeting FDA approval for interchangeable biosimilar insulin—including Icodec, Degludec, Glargine, Detemir, and Aspart—in auto-pens and vials to lower global healthcare costs.
506(e) Outsourcing & Sterile Compounding: Operating under direct FDA oversight (distinct from traditional state-regulated compounding pharmacies) in accordance with cGMP standards (21 CFR Parts 210–211), ISO 13485 certification, and USP Chapter <797> and <800> compliance for sterile injectable fill-finish, Annex 1-compliant sterile fill-finish syringes, sterile injectable compounding, FDA-shortlisted drugs, and bacteriostatic water for injection (BWFI) in multi-dose vials.
Parenteral Drug Delivery Devices & Autoinjector OEM
Insulin & GLP-1 Pen Manufacturing: Ranked the No. 5 leading insulin self-injection device OEM and 3 mL cartridge insulin delivery pen manufacturer with USFDA 506(e) registration, delivering premier GLP-1 peptide pen injector contract manufacturing, GLP-1 pen injector supplier services, and API insulin autopen combination drug production.
Combination Products & Cleanroom Assembly: Premier biologics drug delivery device contract manufacturer, custom pen injector device developer, and elite biopharmaceutical parenteral delivery device supplier offering 21 CFR 4 combination product contract manufacturing, ISO 13485 cleanroom device assembly services, commercial-scale insulin device manufacturing, and high-volume autoinjector assembly for prefilled syringes, epinephrine auto-injectors, insulin pens, rheumatoid arthritis autoinjectors, and MDI/DPI inhalation therapeutics.
Partner with MayMag Biologics—your USA-based CMO insulin manufacturing partner and biomanufacturer built to capture global insulin market share.

Comments
Post a Comment